Eli Lilly and Company Financial Statements (LLY)
|
|
|
|
Report date
|
|
|
23.02.2022 |
22.02.2023 |
21.02.2024 |
19.02.2025 |
12.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
28 318 |
28 541 |
34 124 |
45 043 |
65 179 |
|
72 250 |
|
Operating Income, bln rub |
|
|
7 933 |
8 653 |
10 787 |
17 502 |
29 696 |
|
33 138 |
|
EBITDA, bln rub |
? |
|
8 043 |
8 661 |
8 568 |
15 228 |
27 937 |
|
33 133 |
|
Net profit, bln rub |
? |
|
5 582 |
6 245 |
5 240 |
10 590 |
20 638 |
|
25 275 |
|
|
OCF, bln rub |
? |
|
7 366 |
7 586 |
4 240 |
8 818 |
16 813 |
|
20 480 |
|
CAPEX, bln rub |
? |
|
1 978 |
2 985 |
7 392 |
8 404 |
7 841 |
|
6 901 |
|
FCF, bln rub |
? |
|
5 388 |
4 600 |
-3 152 |
414.3 |
8 972 |
|
13 580 |
|
Dividend payout, bln rub
|
|
|
3 087 |
3 536 |
4 069 |
4 680 |
5 384 |
|
5 586 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
55.3% |
56.6% |
77.7% |
44.2% |
26.1% |
|
22.1% |
|
|
OPEX, bln rub |
|
|
13 073 |
13 258 |
16 255 |
19 123 |
24 919 |
|
27 195 |
|
Cost of production, bln rub |
|
|
7 313 |
6 630 |
7 082 |
8 418 |
10 564 |
|
11 917 |
|
R&D, bln rub |
|
|
6 931 |
7 191 |
9 313 |
10 991 |
13 338 |
|
14 114 |
|
Interest expenses, bln rub |
|
|
339.8 |
331.6 |
485.9 |
780.6 |
795.3 |
|
883.6 |
|
|
Assets, bln rub |
|
|
48 806 |
49 490 |
64 006 |
78 715 |
112 476 |
|
116 576 |
|
Net Assets, bln rub |
? |
|
8 979 |
10 650 |
10 772 |
14 192 |
26 535 |
|
31 198 |
|
Debt, bln rub |
|
|
16 885 |
16 239 |
25 225 |
33 644 |
42 503 |
|
43 370 |
|
Cash, bln rub |
|
|
3 909 |
2 212 |
2 928 |
3 423 |
7 268 |
|
5 282 |
|
Net debt, bln rub |
|
|
12 976 |
14 027 |
22 298 |
30 221 |
35 235 |
|
38 088 |
|
|
Ordinary share price, rub |
|
|
276.2 |
365.8 |
582.9 |
772.0 |
1 075 |
|
977.1 |
|
Number of ordinary shares, mln |
|
|
953.7 |
950.2 |
899.4 |
900.6 |
898.0 |
|
894.5 |
|
|
Market cap, bln rub |
|
|
263 418 |
347 615 |
524 266 |
695 267 |
965 065 |
|
873 971 |
|
EV, bln rub |
? |
|
276 394 |
361 641 |
546 564 |
725 488 |
1 000 300 |
|
912 059 |
|
Book value, bln rub |
|
|
-2 605 |
-630 |
-1 074 |
2 256 |
14 116 |
|
17 694 |
|
|
EPS, rub |
? |
|
5.85 |
6.57 |
5.83 |
11.8 |
23.0 |
|
28.3 |
|
FCF/share, rub |
|
|
5.65 |
4.84 |
-3.50 |
0.46 |
9.99 |
|
15.2 |
|
BV/share, rub |
|
|
-2.73 |
-0.66 |
-1.19 |
2.50 |
15.7 |
|
19.8 |
|
|
EBITDA margin, % |
? |
|
28.4% |
30.3% |
25.1% |
33.8% |
42.9% |
|
45.9% |
|
Net margin, % |
? |
|
19.7% |
21.9% |
15.4% |
23.5% |
31.7% |
|
35.0% |
|
FCF yield, % |
? |
|
2.05% |
1.32% |
-0.60% |
0.06% |
0.93% |
|
1.55% |
|
ROE, % |
? |
|
62.2% |
58.6% |
48.6% |
74.6% |
77.8% |
|
81.0% |
|
ROA, % |
? |
|
11.4% |
12.6% |
8.19% |
13.5% |
18.3% |
|
21.7% |
|
|
P/E |
? |
|
47.2 |
55.7 |
100.0 |
65.7 |
46.8 |
|
34.6 |
|
P/FCF |
|
|
48.9 |
75.6 |
-166.3 |
1 678 |
107.6 |
|
64.4 |
|
P/S |
? |
|
9.30 |
12.2 |
15.4 |
15.4 |
14.8 |
|
12.1 |
|
P/BV |
? |
|
-101.1 |
-551.9 |
-488.0 |
308.3 |
68.4 |
|
49.4 |
|
EV/EBITDA |
? |
|
34.4 |
41.8 |
63.8 |
47.6 |
35.8 |
|
27.5 |
|
Debt/EBITDA |
|
|
1.61 |
1.62 |
2.60 |
1.98 |
1.26 |
|
1.15 |
|
|
R&D/CAPEX, % |
|
|
350.3% |
240.9% |
126.0% |
130.8% |
170.1% |
|
204.5% |
|
|
CAPEX/Revenue, % |
|
|
6.99% |
10.5% |
21.7% |
18.7% |
12.0% |
|
9.55% |
|
| Eli Lilly and Company shareholders |
